The Filing Desk

Cumberland Pharmaceuticals vs Lexicon Pharmaceuticals

Cumberland Pharmaceuticals CPIX · Lexicon Pharmaceuticals LXRX · Pharmaceuticals

Lexicon Pharmaceuticals reported revenue of $50 million in fiscal 2025, about the same as Cumberland Pharmaceuticals' $44 million in fiscal 2025. Cumberland Pharmaceuticals' revenue grew 17.6% in its latest year, and Lexicon Pharmaceuticals' grew 60.2%. Cumberland Pharmaceuticals had an operating margin of -6.3%, against -98.2% at Lexicon Pharmaceuticals. Free cash flow was $5 million at Cumberland Pharmaceuticals and −$68 million at Lexicon Pharmaceuticals.

Side by side

Cumberland PharmaceuticalsLexicon Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$44M$50M
Revenue growth17.6%60.2%
Revenue growth a year, last 5 years3.5%15.7%
Gross margin85.0%99.5%
Operating margin−6.3%−98.2%
Net margin−6.4%−101.1%
Free cash flow$5M−$68M
Free cash flow margin10.9%−136.2%
Return on capital—−105.0%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count5.7%13.4%
Last close$6.30$1.67
P/E at the last close1.4×—
Insider trades, last 12 months—bought $2.7 million, sold $0
Piotroski F-score—4 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Cumberland PharmaceuticalsLexicon Pharmaceuticals
Operating margin
Percent of revenue
Cumberland PharmaceuticalsLexicon Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Cumberland PharmaceuticalsLexicon Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Cumberland Pharmaceuticals and Lexicon Pharmaceuticals pages.